Azelastine‐fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology
Pediatric Allergy and Immunology · 2026-03 · 37 (3)
DOI: 10.1111/pai.70320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 26.02.2026. Verfasst von Gianluigi Marseglia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Fluticasone, Phthalazines, Rhinitis, Allergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Allergic rhinitis (AR) is one of the most prevalent chronic conditions in children and adolescents, significantly impacting quality of life and scholastic performance. Effective management requires therapeutic approaches that address the complex pathophysiology while ensuring safety and tolerability.
Methods
This paper reviews the evidence supporting azelastine‐fluticasone combination intranasal therapy in pediatric allergic rhinitis, with a focus on efficacy, safety, and clinical implementation. This paper encompassed clinical trials, guidelines (ARIA), consensus statements (SIAIP Delphi Consensus), and real‐world evidence gathered from Italian primary care pediatricians managing children and adolescents with AR.
Results
Azelastine‐fluticasone combination therapy demonstrates superior efficacy compared to monotherapy, exhibiting a rapid onset of action (15–30 min) and sustained symptom control. Its dual mechanism effectively addresses both early‐phase (H1‐receptor antagonism) and late‐phase (glucocorticoid anti‐inflammatory effects) allergic responses. Clinical trials conducted in adolescents aged 12–18 years confirm an excellent safety profile, with no significant effects observed on growth or the Hypothalamic–Pituitary–Adrenal (HPA) axis. Emerging evidence further may support its potential utility in younger children aged 6–12 years. The SIAIP Delphi Consensus on AR management, involving 42 pediatricians, achieved over 80% agreement on key management principles, particularly emphasizing the control of type 2 inflammation. Survey data collected from 864 Italian primary care pediatricians, collectively managing 81,231 children, indicates high adherence to ARIA guidelines (exceeding 70%) and a notable increase in the adoption of combination therapy, reaching up to 20% of cases.
Conclusion
Azelastine‐fluticasone combination intranasal therapy represents a significant paradigm shift in pediatric allergic rhinitis management. It offers superior efficacy, an excellent safety profile, and practical advantages that foster better treatment adherence. This therapeutic approach is well‐aligned with contemporary guidelines and is increasingly being adopted in clinical practice for the management of moderate to severe AR in children and adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
- Pediatrics, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Department of Woman and Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy.
- Allergy Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Allergy Clinic, Casa di Cura, Villa Montallegro, Genoa, Italy.
ORCID-Profile: Amelia Licari
Zitieren
APA
Marseglia, G., Miraglia Del Giudice, M., Licari, A., Indolfi, C., Tosca, M. A., & Ciprandi, G. (2026). Azelastine‐fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology. Pediatric Allergy and Immunology, 37(3). https://doi.org/10.1111/pai.70320
Vancouver
Marseglia G, Miraglia Del Giudice M, Licari A, Indolfi C, Tosca MA, Ciprandi G. Azelastine‐fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology. Pediatric Allergy and Immunology. 2026;37(3). doi:10.1111/pai.70320
BibTeX
@article{Marseglia2026,
author = {Marseglia, Gianluigi and Miraglia Del Giudice, Michele and Licari, Amelia and Indolfi, Cristiana and Tosca, Maria Angela and Ciprandi, Giorgio},
title = {Azelastine‐fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology},
journal = {Pediatric Allergy and Immunology},
year = {2026},
volume = {37},
number = {3},
doi = {10.1111/pai.70320}
}
EUVIMED